Fierce Biotech April 25, 2024
Sanofi is narrowing development of one of its 5 billion euro ($5.4 billion), “pipeline-in-a-product” assets. The French drugmaker axed Sjögren’s syndrome from the list of targeted indications for frexalimab after seeing phase 2 efficacy data—and reported a phase 3 flop for one of its tarnished former top prospects.
Frexalimab is a CD40L monoclonal antibody that cleared a midphase test in multiple sclerosis (MS) last year. The readout suggested Sanofi may have found a way around the blood clot risks that blighted earlier CD40 drug candidates. Encouraged, Sanofi pushed ahead with phase 3 studies in two forms of MS and midstage trials in Type 1 diabetes and systemic lupus erythematosus.
The company began comparing frexalimab, also known as SAR441344, to...
Today's Sponsors
Today's Sponsor